ライフサイエンスコーパス: corticosteroid therapy

1 erapy (topical, regionally injected, or oral corticosteroid therapy).

2 ation at 90 and 180 days after initiation of corticosteroid therapy.

3 Both subtypes respond to corticosteroid therapy.

4 nize estrogen-promoted events in response to corticosteroid therapy.

5 engraftment period and favorable response to corticosteroid therapy.

6 the diagnosis, especially before initiating corticosteroid therapy.

7 but aggressive disease that responds well to corticosteroid therapy.

8 1%) patients also having concurrent systemic corticosteroid therapy.

9 ocular hypertensive response with the use of corticosteroid therapy.

10 patients do not respond well to conventional corticosteroid therapy.

11 solved disease and was unrelated to systemic corticosteroid therapy.

12 pients remain without the need for long-term corticosteroid therapy.

13 resses in only a minority of patients during corticosteroid therapy.

14 kin of the abdominal wall that resolved with corticosteroid therapy.

15 roids, and 20 (56%) were able to discontinue corticosteroid therapy.

16 ascular protective effect of acute high-dose corticosteroid therapy.

17 was reversed with the prompt institution of corticosteroid therapy.

18 grade I and IIA and were fully reversed with corticosteroid therapy.

19 ients (38%) developed diabetes during pulsed corticosteroid therapy.

20 month and 2 gm thereafter; and conventional corticosteroid therapy.

21 tient was successfully treated using topical corticosteroid therapy.

22 tructive pulmonary disease (COPD) respond to corticosteroid therapy.

23 0.20, n = 19, p < 0.001) and normalizes with corticosteroid therapy.

24 s documented in patients receiving long-term corticosteroid therapy.

25 veitis, which are often managed with chronic corticosteroid therapy.

26 nd one of complications related to long-term corticosteroid therapy.

27 ion of the effusion after the institution of corticosteroid therapy.

28 sed neutrophils and often poorly responds to corticosteroid therapy.

29 evere pain, and a rapid response to systemic corticosteroid therapy.

30 loped clinical skin GVHD, which responded to corticosteroid therapy.

31 commonly in patients who deteriorated during corticosteroid therapy.

32 It appears unresponsive to corticosteroid therapy.

33 ation of cyclophosphamide and institution of corticosteroid therapy.

34 pneumonitis is reversible and may respond to corticosteroid therapy.

35 of a 58-year-old patient undergoing empiric corticosteroid therapy.

36 t, or by differences in the use of antenatal corticosteroid therapy.

37 Nine patients received corticosteroid therapy.

38 iving patients required maintenance low-dose corticosteroid therapy.

39 erlying chronic inflammatory disease or from corticosteroid therapy.

40 OR, 2.12; 95% CI, 1.36-3.29) associated with corticosteroid therapy.

41 symptomatic and endoscopic remission without corticosteroid therapy.

42 overlap syndrome might benefit from inhaled corticosteroid therapy.

43 to inhaled beta-agonist, antimuscarinic, and corticosteroid therapy.

44 on (n = 1), which resolved following topical corticosteroid therapy.

45 due to DRESS is poor and was not improved by corticosteroid therapy.

46 erage 5.5 months following the initiation of corticosteroid therapy.

47 oimmune-like hepatitis that is responsive to corticosteroid therapy.

48 dermatitis that was unresponsive to topical corticosteroid therapy.

49 Single and multiple courses of antenatal corticosteroid therapy.

50 linical examination as well as with systemic corticosteroid therapy.

51 all patients, and none responded to topical corticosteroid therapy.

52 % in ED visits, and 46% in the need for oral corticosteroid therapy.

53 asthma in spite of high-dose inhaled or oral corticosteroid therapy.

54 epartment (ED) visits, and the need for oral corticosteroid therapy.

55 less responsive to the beneficial effects of corticosteroid therapy.

56 mately 20% of icteric AIH presentations fail corticosteroid therapy.

57 lowing intravenous gamma globulin (IVIG) and corticosteroid therapy.

58 In respect to systemic corticosteroid therapy, 10 patients (18 of 51 eyes) were

59 layed resistance to combined vinblastine and corticosteroid therapy (21.9% v 3.3%; P = .001), showed

60 Most studies have reported that corticosteroid therapy adversely influences influenza-re

61 rgeted trough levels of 5 to 7 ng/ml) and no corticosteroid therapy after the first week.

62 ral nutrition therapy is more effective than corticosteroid therapy alone in patients with severe AH.

63 d airway function when compared with inhaled corticosteroid therapy alone.

64 that cyclophosphamide therapy is superior to corticosteroid therapy alone.

65 All patients responded well to systemic corticosteroid therapy, although some had a relapse upon

66 All patients had failed high dose corticosteroid therapy and 144 (85%) of the 169 patients

67 erage 4.2 months following the initiation of corticosteroid therapy and 8% (9/105) were intolerant to

68 p avoid unnecessary morbidity from high-dose corticosteroid therapy and allow the most appropriate an

69 The role of systemic corticosteroid therapy and aspirin in NA-AION and of thr

70 be a biomarker for responsiveness to inhaled corticosteroid therapy and may help identify patients as

71 patitis of undetermined cause can respond to corticosteroid therapy and represent autoantibody-negati

72 ts with severe asthma are less responsive to corticosteroid therapy and show increased airway remodel

73 ray of effector T cells that persist despite corticosteroid therapy and sustain chronic, smoldering v

74 ant association between antecedent high-dose corticosteroid therapy and the development of SRC.

75 As adjunctive corticosteroid therapy and vitamin D have immunomodulato

76 in both blood and lung tissue in relation to corticosteroid therapy and vitamin D levels, especially

77 However, the efficacy of corticosteroid therapy and whether the therapy should be

78 myopathy who had not responded adequately to corticosteroid therapy and whose clinical course was fur

79 90% (881) of the patients used inhaled corticosteroid therapy, and all patients continued to us

80 ntaneously--only to relapse after receipt of corticosteroid therapy, and clear again, 8.5 years later

81 but aggressive disease that responds well to corticosteroid therapy, and human leukocyte antigen DR4

82 Autoimmune hepatitis commonly relapses after corticosteroid therapy, and long-term management strateg

83 Early corticosteroid therapy appears to be critical for revers

84 ith severe asthma who require long-term oral corticosteroid therapy are at risk of unwanted effects.

85 infusion (IVIG), with or without additional corticosteroid therapy, are common options, but optimal

86 y high-volume saline irrigation with topical corticosteroid therapy as a first-line therapy for chron

87 The second case outlines the use of topical corticosteroid therapy as an adjunct to non-surgical per

88 y biliary cirrhosis entered remission during corticosteroid therapy as commonly as individuals with d

89 portion of patients who discontinued inhaled corticosteroid therapy as part of a phased-reduction pro

90 logical cirrhosis at presentation respond to corticosteroid therapy as well as patients without cirrh

91 whether benefit exists to combination NSAID/corticosteroid therapy, as well as whether NSAIDS can re

92 sits, and 44% reduction in the need for oral corticosteroid therapy at 48 months, the model simulated

93 High-dose corticosteroid therapy at diagnosis of mold infection wa

94 e patients had received a course of systemic corticosteroid therapy at the time of MB.

95 is not needed, but using concomitant pulsed corticosteroid therapy beyond 3 to 5 days requires an in

96 toms and infiltrates regressed after topical corticosteroid therapy, but recurred after each adalimum

97 disease persisted for nearly a month despite corticosteroid therapy, but resolved.

98 Autoimmune hepatitis may fail to respond to corticosteroid therapy, but the frequency and bases for

99 conclusion, patients who respond to initial corticosteroid therapy can achieve a sustained remission

100 Corticosteroid therapy can be effective in patients with

101 utcomes in subjects randomized to continuous corticosteroid therapy (CCS) or early corticosteroid wit

102 ompare patterns of weight gain under chronic corticosteroid therapy (CCST) with that observed under e

103 Corticosteroid therapy consisted of either methylprednis

104 AMG 853 as an add-on to inhaled corticosteroid therapy demonstrated no associated risks

105 t high risk for asthma, two years of inhaled-corticosteroid therapy did not change the development of

106 compared with a single course, of antenatal corticosteroid therapy did not increase or decrease the

107 hil count is a promising biomarker to direct corticosteroid therapy during COPD exacerbations, but la

108 he usefulness of blood eosinophils to direct corticosteroid therapy during exacerbations.

109 , and systemic corticosteroid ( sCS systemic corticosteroid ) therapy effects were assessed in compar

110 adequately controlled asthma despite inhaled corticosteroid therapy, especially in periostin-high pat

111 systemic side effects compared with regional corticosteroid therapy, except for greater antibiotic us

112 s 50 years or older (or 40 years or older on corticosteroid therapy) expected to require NSAIDs for 1

113 gh in patients without and with sCS systemic corticosteroid therapy for 5 days or fewer (area under t

114 decreased in patients receiving sCS systemic corticosteroid therapy for 6-14 days.

115 that children who receive long-term inhaled corticosteroid therapy for asthma have height deficits 1

116 y of colchicine as an alternative to inhaled corticosteroid therapy for asthma is unknown.

117 Siplizumab administered with corticosteroid therapy for grade II or higher acute GVHD

118 regional corticosteroid injections and oral corticosteroid therapy for induction of remission.

119 s, with important limitations, suggests that corticosteroid therapy for presumed influenza-associated

120 observational studies investigating systemic corticosteroid therapy for presumed influenza-associated

121 spine occurred in association with long-term corticosteroid therapy for systemic lupus erythematosus.

122 t-line therapy for mild to moderate UC, with corticosteroid therapy for those who fail to achieve rem

123 rance that the potential benefits of topical corticosteroid therapy, for treating pain and discomfort

124 Inhaled corticosteroid therapy has proven efficacy for asthmatic

125 ly completed randomized, controlled studies, corticosteroid therapy has proven to be efficacious in t

126 Corticosteroid therapy has shown some benefit in severe

127 Nonadherence to inhaled corticosteroid therapy (ICS) is a major contributor to p

128 Topical corticosteroid therapy improved overall symptom scores (

129 , and intracranial pressure decreased during corticosteroid therapy in all three.

130 tion to the variation in response to inhaled corticosteroid therapy in asthma.

131 a useful alternative to the over-reliance on corticosteroid therapy in atopic disease.

132 spitalizations, ED visits, and need for oral corticosteroid therapy in childhood asthma for planning

133 The effect of corticosteroid therapy in critically ill patients with l

134 No consensus exists for adjusting inhaled corticosteroid therapy in patients with asthma.

135 placebo-controlled trial the effects of oral corticosteroid therapy in patients with exacerbations of

136 ed the risk of UGIB; concomitant nsNSAID and corticosteroid therapies increased the IRR to the greate

137 Corticosteroid therapy is frequently used in septic pati

138 A single course of antenatal corticosteroid therapy is recommended for pregnant women

139 intervention; long-term therapy with inhaled corticosteroid therapy is safer than frequent bursts of

140 disease progression can be avoided if timely corticosteroid therapy is started.

141 Although corticosteroid therapy is the primary treatment for thes

142 Corticosteroid therapy is typically administered when a

143 le airway obstruction, withdrawal of inhaled corticosteroid therapy leads to a deterioration in venti

144 Eventually corticosteroid therapy led to complete and long lasting

145 Repeated lumbar punctures and corticosteroid therapy led to improvement in symptoms in

146 wing the institution of cyclophosphamide and corticosteroid therapy, longer-term management issues ca

147 evated C3a and anti-dsDNA levels, short-term corticosteroid therapy may avert a severe flare.

148 in animals and children have suggested that corticosteroid therapy may be a useful adjunct to conven

149 Adjunctive topical corticosteroid therapy may be associated with improved l

150 ds on cytokine synthesis in T cells, chronic corticosteroid therapy may indirectly exacerbate the lon

151 Use of prehospital systemic corticosteroid therapy may prevent the development of ac

152 Early corticosteroid therapy may prevent the development of su

153 For hospitalized adults with CAP, systemic corticosteroid therapy may reduce mortality by approxima

154 Although cycloplegic and corticosteroid therapy may resolve some entities, pars p

155 hCRF, as an alternative to corticosteroid therapy, may provide substantial benefits

156 ting that retinal vasculitis unresponsive to corticosteroid therapy maybe a poor prognostic sign.

157 Studies have suggested that primary corticosteroid therapy might be beneficial and that adve

158 ed assay, those seropositive by ELISA failed corticosteroid therapy more commonly (24% vs. 3%, P = .0

159 After intensified local corticosteroid therapy, most patients show stable visual

160 derate asthma controlled by low-dose inhaled corticosteroid therapy (n = 114 assigned to physician as

161 tional symptoms, prompt response to systemic corticosteroid therapy, neutrophilia, and abrupt onset o

162 ients and assess the effect of ribavirin and corticosteroid therapy on the case-fatality rate, strati

163 aze scores of 0 or 0.5+ in both eyes without corticosteroid therapy or uveitis worsening.

164 ated with bolus impaction: swallowed topical corticosteroid therapy (OR 0.411, 95%-CI 0.203-0.835, P

165 istic regression modeling: swallowed topical corticosteroid therapy (OR 0.503, 95%-CI 0.255-0.993, P

166 itial pneumonia generally responds poorly to corticosteroid therapy, other forms of interstitial pneu

167 han those without to have received intensive corticosteroid therapy (P<0.007), had virus isolated fro

168 Despite the efficacy of corticosteroid therapy, patients hospitalized for asthma

169 an antilymphocyte preparation plus high dose corticosteroid therapy prior to conversion.

170 Corticosteroid therapy provides immediate benefit and ma

171 Corticosteroid therapy reduces or prevents hepatic fibro

172 Corticosteroid therapy reduces the duration and severity

173 years, systemic adverse effects from inhaled corticosteroid therapy remains a complicated and controv

174 Postoperative corticosteroid therapy remains an area of debate without

175 Low-dose corticosteroid therapy reversed shock and showed nonsign

176 echanistic basis of the variable response to corticosteroid therapy seen in patients with AAH and to

177 tion of ipratropium bromide to albuterol and corticosteroid therapy significantly decreases the hospi

178 al insufficiency animal model, we found that corticosteroid therapy significantly improved the surviv

179 domized controlled trial has been published, corticosteroid therapy, surgical decompression or observ

180 Patients were also randomly assigned to corticosteroid therapy that included either dexamethason

181 In all IAC patients, after 4 and 8 weeks of corticosteroid therapy the contribution of these IgG4+ c

182 tent asthma controlled with low-dose inhaled corticosteroid therapy, the use of either biomarker-base

183 ving tacrolimus/sirolimus and withdrawn from corticosteroid therapy three months after transplantatio

184 eases after more than 5 days of sCS systemic corticosteroid therapy; thus, imaging should not be dela

185 e contributions of systemic inflammation and corticosteroid therapy to bone loss.

186 However, the ability of corticosteroid therapy to improve mortality in patients

187 pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interfero

188 Treatment can be improved by continuing corticosteroid therapy until normal liver test results a

189 ortion in whom complete cessation of inhaled corticosteroid therapy was achieved (17.4 percent in the

190 Using a Cox proportional hazards model, corticosteroid therapy was associated with similar 30-da

191 AT and subsequently at the time that topical corticosteroid therapy was initiated.

192 In logistic regression models, corticosteroid therapy was not associated with reduction

193 children with bacterial meningitis, adjuvant corticosteroid therapy was not associated with time to d

194 Systemic corticosteroid therapy was not significantly associated

195 Recently high-dose corticosteroid therapy was shown to reduce the duration

196 Intensified topical corticosteroid therapy was started immediately after dia

197 Corticosteroid therapy was the treatment of choice in 38

198 Adverse events associated with corticosteroid therapy were mild and transient.

199 tis patients aged >or=50 years (or >or=40 on corticosteroid therapy) were randomly assigned to rofeco

200 -host disease (GVHD) from receiving systemic corticosteroid therapy, which impairs cellular immunity.

201 e anterior segment and manageable with local corticosteroid therapy, which justified the continuation

202 his study compares the analgesic efficacy of corticosteroid therapy with placebo.

203 to severe UC should undergo a course of oral corticosteroid therapy, with transition to 5-ASA, thiopu

204 ifying children who are likely responders to corticosteroid therapy would be a major benefit in the m